TrialEuropean heart journal2023

Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.

Michael Bhm et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.